No licensed hantavirus vaccine exists for New World strains such as Andes or Sin Nombre viruses responsible for most U.S. and Latin American cases, with all candidates remaining in preclinical or early Phase 1 stages as of September 2026. mRNA platforms from Moderna-Korea University and UTMB have shown strong protection in rodent models, including single-dose efficacy against Andes virus, while older DNA vaccines targeting Hantaan/Puumala have completed small Phase 1 safety and immunogenicity trials but lack Phase 3 efficacy data. Low disease incidence complicates large-scale human testing, and recent outbreaks like the MV Hondius cluster have boosted research interest without shifting regulatory timelines. Trader consensus reflects the multi-year requirements for Phase 2/3 trials, manufacturing scale-up, and approvals, though accelerated funding or emergency authorization after a major event could theoretically compress the schedule.